-
Je něco špatně v tomto záznamu ?
Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions
J. Blatný, J. Astermark, C. Catarino, G. Dolan, K. Fijnvandraat, C. Hermans, K. Holstein, V. Jiménez-Yuste, R. Klamroth, M. Lavin, PJ. Lenting, S. Lobet, ME. Mancuso, J. Motwani, JS. O'Donnell, C. Königs
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2019
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
ProQuest Central
od 2016-02-01
Nursing & Allied Health Database (ProQuest)
od 2016-02-01
Health & Medicine (ProQuest)
od 2016-02-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Over recent decades, management of people with hemophilia (PwH) has been greatly improved by scientific advances that have resulted in a rich and varied therapeutic landscape. Nevertheless, treatment limitations continue to drive innovation, and emerging options have the potential to realize further improvement. We advocate four general principles to optimize benefits from innovation: individualizing the treatment approach, targeting 'normal,' making the most of available resources, and considering treatment affordability. Ultimately, all PwH-men and women, of all ages and severities, and worldwide-should have access to treatment that fully prevents bleeding, while allowing personal, social, family, and professional lives of choice. Clearly, we are not there yet, but developing goals/milestones based on the principles we describe may help to achieve this.
Centre for Haemostasis and Thrombosis St Thomas' Comprehensive Care Centre London UK
Department of Haematology and Oncology University Medical Centre Hamburg Eppendorf Hamburg Germany
Department of Paediatric Haematology Birmingham Children's Hospital Birmingham UK
Hospital Bory Nemocnica Bory a s Ivana Kadlečíka 2 Bratislava 841 06 Slovakia
National Coagulation Centre St James' Hospital Dublin Ireland
Neuromusculoskeletal Lab Brussels Belgium
University Hospital Brno Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002451
- 003
- CZ-PrNML
- 005
- 20250123101930.0
- 007
- ta
- 008
- 250117e20240930enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/20406207241285143 $2 doi
- 035 __
- $a (PubMed)39381602
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Blatný, Jan $u Hospital Bory, Nemocnica Bory, a.s., Ivana Kadlečíka 2, Bratislava 841 06, Slovakia $u University Hospital Brno, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000162619157 $7 xx0034546
- 245 10
- $a Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions / $c J. Blatný, J. Astermark, C. Catarino, G. Dolan, K. Fijnvandraat, C. Hermans, K. Holstein, V. Jiménez-Yuste, R. Klamroth, M. Lavin, PJ. Lenting, S. Lobet, ME. Mancuso, J. Motwani, JS. O'Donnell, C. Königs
- 520 9_
- $a Over recent decades, management of people with hemophilia (PwH) has been greatly improved by scientific advances that have resulted in a rich and varied therapeutic landscape. Nevertheless, treatment limitations continue to drive innovation, and emerging options have the potential to realize further improvement. We advocate four general principles to optimize benefits from innovation: individualizing the treatment approach, targeting 'normal,' making the most of available resources, and considering treatment affordability. Ultimately, all PwH-men and women, of all ages and severities, and worldwide-should have access to treatment that fully prevents bleeding, while allowing personal, social, family, and professional lives of choice. Clearly, we are not there yet, but developing goals/milestones based on the principles we describe may help to achieve this.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Astermark, Jan $u Department of Translational Medicine, Lund University, and Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden
- 700 1_
- $a Catarino, Cristina $u Immunochemotherapy Department, Congenital Coagulopathies Comprehensive Care Centre, Santa Maria University Hospital, Lisbon University, Lisbon, Portugal
- 700 1_
- $a Dolan, Gerry $u Centre for Haemostasis and Thrombosis, St Thomas' Comprehensive Care Centre, London, UK
- 700 1_
- $a Fijnvandraat, Karin $u Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, Netherlands
- 700 1_
- $a Hermans, Cédric $u Division of Haematology, Saint-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium $1 https://orcid.org/0000000154298437
- 700 1_
- $a Holstein, Katharina $u Department of Haematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000337530972
- 700 1_
- $a Jiménez-Yuste, Víctor $u Department of Haematology, La Paz University Hospital-IdiPaz, Autónoma University of Madrid, Madrid, Spain $1 https://orcid.org/0000000339373499
- 700 1_
- $a Klamroth, Robert $u Department of Internal Medicine, Vivantes Hospital Friedrichshain, Berlin, Germany, and Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany
- 700 1_
- $a Lavin, Michelle $u Irish Centre for Vascular Biology, School of Pharmacy and Biomedical Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland $u National Coagulation Centre, St. James' Hospital, Dublin, Ireland
- 700 1_
- $a Lenting, Peter J $u Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITh U1176, 94276, Le Kremlin-Bicêtre, France
- 700 1_
- $a Lobet, Sébastien $u Service d'ergothérapie et de kinésithérapie, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium $u Neuromusculoskeletal Lab (NMSK), Secteur des Sciences de la Santé, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain (UCLouvain), Brussels, Belgium $1 https://orcid.org/0000000238296850
- 700 1_
- $a Mancuso, Maria Elisa $u Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy and Humanitas University, Pieve Emanuele, Milan, Italy $1 https://orcid.org/0000000271134028
- 700 1_
- $a Motwani, Jayashree $u Department of Paediatric Haematology, Birmingham Children's Hospital, Birmingham, UK
- 700 1_
- $a O'Donnell, James S $u Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
- 700 1_
- $a Königs, Christoph $u Goethe University, University Hospital Frankfurt, Department of Paediatrics and Adolescent Medicine, Frankfurt, Germany
- 773 0_
- $w MED00205356 $t Therapeutic advances in hematology $x 2040-6207 $g Roč. 15 (20240930), s. 20406207241285143
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39381602 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250123101924 $b ABA008
- 999 __
- $a ok $b bmc $g 2254581 $s 1238454
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 15 $c - $d 20406207241285143 $e 20240930 $i 2040-6207 $m Therapeutic advances in hematology $n Ther Adv Hematol $x MED00205356
- LZP __
- $a Pubmed-20250117
